MedPath
HSA Approval

LITFULO CAPSULE 50MG

SIN17041P

LITFULO CAPSULE 50MG

LITFULO CAPSULE 50MG

July 5, 2024

PFIZER PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPFIZER PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

L04AF08

Manufacturer Information

PFIZER PRIVATE LIMITED

Pfizer Manufacturing Deutschland GmbH

Active Ingredients

Ritlecitinib Tosylate equivalent to Ritlecitinib

50mg

Ritlecitinib

Documents

Package Inserts

Litfulo Capsule PI.pdf

Approved: July 5, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LITFULO CAPSULE 50MG - HSA Approval | MedPath